Last reviewed · How we verify
TQ-A3334
At a glance
| Generic name | TQ-A3334 |
|---|---|
| Sponsor | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Evaluate TQ-A3334 Combined Nucleoside (Acid) Analogs in the First Treatment/Treatment of Chronic HBV Infection (PHASE2)
- A Clinical Trial of TQ-A3334 Tablet After Multiple Administration in Adult Subjects (PHASE1)
- A Clinical Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 Tablets (PHASE1, PHASE2)
- A Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 Tablets (PHASE1, PHASE2)
- Combination of ETV, TQ-A3334 and TQ-B2450 for CHB (Neptune Study) (PHASE2)
- A Study of TQ-A3334 Combined With Entecavir in the Treatment of Chronic Hepatitis B (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TQ-A3334 CI brief — competitive landscape report
- TQ-A3334 updates RSS · CI watch RSS
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. portfolio CI